Skip to main content
. 2020 Nov 25;15(1):27–42. doi: 10.1002/1878-0261.12673

Fig. 3.

Fig. 3

Heterogeneity in response to MEK inhibitors in NRAS mutant lung cancer cell lines. (A) The NRAS mutant lung cancer cell lines were treated with increasing doses of MEK inhibitors (trametinib and selumetinib). The cell viability was assessed by MTS after 72 h. (B) DFCI168, H2087, and H2347 were treated with trametinib at the indicated concentration for the indicated times. The cell extracts were immunoblotted using the indicated antibodies.